0001209191-23-028813.txt : 20230511
0001209191-23-028813.hdr.sgml : 20230511
20230511170444
ACCESSION NUMBER: 0001209191-23-028813
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230428
FILED AS OF DATE: 20230511
DATE AS OF CHANGE: 20230511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 23912079
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-28
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO STREET
SAN RAFAEL
CA
94901
1
1
0
0
Chief Executive Officer
1
Common Stock
2023-04-28
5
A
0
E
317
66.88
A
426213
D
Common Stock
2023-05-09
4
M
0
30000
67.81
A
456213
D
Common Stock
2023-05-09
4
S
0
13626
94.22
D
442587
D
Common Stock
2023-05-09
4
S
0
14964
95.49
D
427623
D
Common Stock
2023-05-09
4
S
0
1410
95.90
D
426213
D
Common Stock
2023-05-10
4
M
0
30000
67.81
A
456213
D
Common Stock
2023-05-10
4
S
0
21453
94.65
D
434760
D
Common Stock
2023-05-10
4
S
0
8547
95.34
D
426213
D
Common Stock
247333
I
Shares held by Jean-Jacques Bienaime Family Trust
Common Stock
100
I
Shares held as UTMA custodian for child
Common Stock
100
I
Shares held as UTMA custodian for child
Stock Option (Right to Buy Common Stock)
67.81
2023-05-09
4
M
0
30000
0.00
D
2013-11-15
2023-05-14
Common Stock
30000
99130
D
Stock Option (Right to Buy Common Stock)
67.81
2023-05-09
4
M
0
30000
0.00
D
2013-11-15
2023-05-14
Common Stock
30000
69130
D
Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan.
Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
The price in column 4 is the weighted average price. The price actually received ranged from $93.85 to $94.83. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
The price in column 4 is the weighted average price. The price actually received ranged from $94.86 to $95.85. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
The price in column 4 is the weighted average price. The price actually received ranged from $95.86 to $95.97. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
The price in column 4 is the weighted average price. The price actually received ranged from $94.12 to $95.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
The price in column 4 is the weighted average price. The price actually received ranged from $95.115 to $95.81. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Eric Fleekop, Attorney-in-Fact
2023-05-11